de Campos E P, Meira D A, Mendes R P, de Campos C E
Rev Bras Pesqui Med Biol. 1978 Dec;11(6):369-76.
The authors have studied a new antibiotic Tobramycin in 30 patients with acute infectious pulmonary disease, denominated type I, II and III, according to associated factors, severity and previous pulmonary alterations, being 29 patients included in type II and III. The pneumonia diagnosis has obeyed to clinical, laboratorial, radiological and microbiological criteria. The results after the Tobramycin therapy in 28 evaluable cases were: 3 failures and 25 therapeutic successes. The gram negative bacteria predominated among the causative pathogens and, in 14 patients, strains of Klebisiella Enterobacter group were isolated. The M.I.C. for the pathogenic isolated bacteria in acute pulmonary processes was less than 1,0 microgram/ml in 26 cases. Adverse reactions were observed in 13 patients, from which 9 have presented only laboratorial alterations. The remaining 4 patients have also presented clinical manifestations. These findings were similar to those reported for other aminoglicosides.
作者对30例急性感染性肺病患者研究了一种新型抗生素妥布霉素，根据相关因素、严重程度和既往肺部病变情况将其分为I、II和III型，其中29例患者属于II型和III型。肺炎诊断依据临床、实验室、放射学和微生物学标准。在28例可评估病例中，妥布霉素治疗后的结果为：3例治疗失败，25例治疗成功。革兰氏阴性菌在致病病原体中占主导，14例患者分离出克雷伯菌属肠杆菌群菌株。急性肺部感染过程中分离出的致病细菌的最低抑菌浓度（M.I.C.）在26例病例中低于1.0微克/毫升。13例患者出现不良反应，其中9例仅出现实验室指标改变。其余4例患者也出现了临床表现。这些发现与其他氨基糖苷类药物的报道相似。
